Dr. Frederick Greene, our Consulting Medical Officer has leveraged his extensive surgical experience and his ongoing editorial experiences with the AJCC and CoC to drive several initiatives for CRStar - including the industry's first podcast focused on Cancer Registry.
Tumors When we think of aggressive cutaneous malignancies, melanoma is often the primary focus. However, the Merkel cell tumor is an additional neoplasm that appears less frequently in abstract accessions. A recent comparative study using SEER (Surveillance, Epidemiology, and End Results) data from 2000 to 2021 examined the epidemiology and malignant behavior of both Merkel […]
Reevaluating Treatment for Stage III Endometrial Cancer Data on gynecological malignancies are essential for hospital, state, and national cancer registries, enabling outcome studies that compare various treatment approaches. For stage III endometrial cancer, treatment options include radiotherapy and, more recently, chemotherapy. However, whether combining these modalities improves survival outcomes remains uncertain. A recent phase 3 […]
Can Low-Dose Aspirin Reduce Colorectal Cancer Recurrence? The benefits of low-dose aspirin have been debated for years, particularly regarding its role in reducing coronary disease. However, its potential in preventing and managing colorectal cancer (CRC) has gained significant attention. A recent study found that low-dose aspirin reduced CRC recurrence by over 50% in patients whose […]
Predicting Cancer Recurrence One of the most frequent questions from patients is whether their cancer will come back after their surgical, radiation, or chemotherapy treatment is complete. Analyses of circulating tumor cells or the DNA associated with those cells (ctDNA) may be the answers. Can postoperative circulating tumor DNA (ctDNA) status predict recurrence-free survival (RFS) […]
The Disruption and Recovery of Cancer Diagnoses Following COVID-19 As we begin 2025, discussions of flu-like illnesses are extremely relevant, especially ongoing issues related to the COVID-19 pandemic. A critical question to consider is: to what extent was cancer detection in the U.S. disrupted during the pandemic's first year, and how much progress was made […]
